After US Launch Bottlenecks, Novo Nordisk Pushes European Rollout For Wegovy In 2023
Novo Nordisk A/S (NYSE: NVO) will roll out its obesity treatment, Wegovy (semaglutide), in Europe in 2023 to ensure it has enough supply.
Bloomberg Reported Earlier Novo Nordisk’s Obesity Drug Wegovy’s European Rollout Delayed After US Setbacks
https://www.bloomberg.com/news/articles/2022-12-13/novo-nordisk-delays-europe-obesity-drug-rollout-to-ensure-supply
Stocks That Hit 52-Week Lows On Thursday
During Thursday's session, 108 stocks hit new 52-week highs.
Jim Simons ‘The Man Who Solved The Market’ Sold 3 Healthcare Dividend Payers, But Upped Stake In This One By 153%
Jim Simons is the founder and hedge fund manager of Renaissance Technologies, which currently has a total portfolio value north of $77 billion, per Stock Circle. This hedge fund uses a quantitative strategy in determining its stock trades.
United Therapeutics, Super Micro Computer, Novo Nordisk And Other Big Gainers From Wednesday
U.S. stocks closed lower on Wednesday, with the Dow Jones dropping more than 500 points. Here is the list of some big stocks recording gains in the previous session.
Why Novo Nordisk A/S Shares Are Shooting Higher Today
Novo Nordisk A/S (NYSE: NVO) shares are trading higher by 7.57% to $114.49 after the company reported third-quarter EPS and sales results were higher year-over-year. The company also raised FY22 operating profit growth guidance.
What Happened?
Novo Nordisk Raises FY22 Earnings Outlook On Robust Ozempic Sales
Novo Nordisk A/S (NYSE:NVO) reported that its 9-month operating profit increased by 28% Y/Y and 14% at constant exchange rates…
Novo Nordisk: Q3 Earnings Insights
Novo Nordisk (NYSE:NVO) reported its Q3 earnings results on Wednesday, November 2, 2022 at 01:30 AM.
Here's what investors need to know about the announcement.
Earnings
Novo Nordisk beat estimated earnings by 3.61%, reporting an EPS of $0.86 versus an estimate of $0.83.
Novo Nordisk Expects FY22 Operating Profit Growth Of 13-16%, Compared To Prior Guidance Of 11-15%.
The company sees FY22 sales growth of 14-17% at CER higher than the prior guidance of 12-16%.
Novo Nordisk Q3 EPS DKK6.34 Up From DKK5.27 YoY, Sales DKK45.57B Up From DKK35.62B YoY
Novo Nordisk (NYSE:NVO) reported quarterly earnings of DKK6.34 per share. This is a 20.3 percent increase over earnings of DKK5.27 per share from the same period last year. The company reported DKK45.57 billion in sales